uniQure N.V.
Close on Oct 19, 2026
- Market cap
- $1.47B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | Before market open | $5.80M | $-1.22 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $3.60M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 2, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $3.70M | $-1.38 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | Before market open | $5.30M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | Before market open | $1.60M | $-0.82 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | $2.30M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | $11.10M | $-1.16 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Press releases
Announcements uniQure filed with the SEC
LEADERSHIP IN GENE THERAPY SEPTEMBER 2026 | 2
Regulation FD disclosure · EX-99.1 to Form 8-K
Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued
Regulation FD disclosure · EX-99.2 to Form 8-K
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
Pricing of Upsized $225 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Plan for BLA Submission for AMT-130 in
Other events · EX-99.1 to Form 8-K
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company
Results of operations · EX-99.1 to Form 8-K
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington ’ s Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces 2025 Financial Results and Provides Recent Company
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LEADERSHIP IN GENE THERAPY JANUARY 2026 | 2
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces Type A Meeting Scheduled with FDA
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Provides Regulatory Update on AMT-130 for Huntington ’ s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
uniQure Announces Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
uniQure Provides Regulatory Update on AMT-130 for Huntington ’ s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pricing of Upsized $300 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington ’ s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
uniQure Announces Second Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Regulatory Update on AMT-130 for Huntington’s Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
uniQure Announces 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Pricing of its Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces Orphan Drug Designation Granted to
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
Material agreement · Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Sale of Commercial Manufacturing Facility to Genezen
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT)
Regulation FD disclosure · EX-99.1 to Form 8-K
uniQure Announces First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
~ Presented promising clinical update from U.S.
Results of operations · EX-99.1 to Form 8-K
Update on Phase I/II Clinical Trials of AMT-130
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K